Wound Healing News and Research

RSS

NeoStem opens new adult stem cell collection center in Austin, TX

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010.

13 Apr 2010

Cytomedix to acquire Sorin's Angel blood separation system and activAT Autologous Thrombin Processing Kit

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.

13 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

SANUWAVE Health announces completion of patient enrollment in dermaPACE Phase III clinical trial

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that patient enrollment was completed in March in its dermaPACE™ Phase III pivotal, randomized, double-blinded, sham controlled, multicenter clinical trial comparing its Pulsed Acoustic Cellular Expression technology, utilizing the dermaPACE™ tissue regeneration device, to sham control for the treatment of diabetic foot ulcers.

6 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months and fiscal year ended December 31, 2009.

1 Apr 2010

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, reports its financial results for the fourth quarter and full year ended December 31, 2009, and on its progress for the year.

31 Mar 2010

Cryo-Cell International, MOSI partner to develop educational exhibit on stem cells and regenerative science

Cryo-Cell International Inc., a global leader of innovative stem cell solutions and stem cell cryopreservation services, today announced plans to partner with Museum of Science & Industry (MOSI) in the development and launch of an interactive educational exhibit on stem cells and regenerative science. Cryo-Cell is one of the most established private family cord blood banks and is a pioneer in the stem cell industry.

31 Mar 2010

Gene expression in breast tissue may help explain pregnancy-associated breast cancer

Expression of inflammatory-related genes in breast tissue of women who have previously given birth may explain the aggressiveness and frequency of pregnancy-associated breast cancer, according to new research at the University of Illinois at Chicago.

30 Mar 2010

Helix BioMedix reports revenue of approximately $391,000 in 2009

Helix BioMedix, Inc., a developer of bioactive peptides, announced financial results for the year ended December 31, 2009.

26 Mar 2010

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Two key, independent proof-of-concept studies conducted for NellOne Therapeutics, Inc. demonstrate the potential efficacy of the company’s lead therapeutic candidate for both skeletal muscle wound healing and myocardial infarction.

26 Mar 2010

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.

23 Mar 2010

Treating RNA segment in wounds may increase protein levels for growth of skin cells

Scientists have determined that chronic wounds might have trouble healing because of the actions of a tiny piece of a molecular structure in cells known as RNA.

23 Mar 2010

Study provides new perspective on cell movements

When cells move about in the body, they follow a complex pattern similar to that which amoebae and bacteria use when searching for food, a team of Vanderbilt researchers have found.

17 Mar 2010

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that significantly adds to the current patent coverage for the Company's NIMBUS technology.

17 Mar 2010

Bovie Medical reports revenues totalling $6.5M for fourth-quarter 2009

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the fourth quarter and year ended December 31, 2009.

16 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Helix BioMedix enters into distribution agreement with RubyDerm Bio

Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

11 Mar 2010

Advitech receives product licence for psoriasis treatment product

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today that the Natural Health Products Directorate (NHPD) has issued to Advitech, on March 8, 2010, a Natural Product Number (NPN) for one of its main products, XP-828L/Dermylex.